Evaluating Novel Cardio-Renal Candidates in the Era of Standard-of-Care: The SDT Fatty Rat Solution
CLEA Japan Scientific Presentation at Kidney Week 2026
At Kidney Week 2026 in Denver, CO, CLEA Japan presented landmark translational data validating the Spontaneously Diabetic Torii (SDT) fatty rat as a premier model for Cardiovascular-Kidney-Metabolic (CKM) syndrome and Diabetic Kidney Disease (DKD).
As SGLT2 inhibitors, GLP-1RAs, and ACEi/ARBs become universal Standards of Care (SoC), proving the ADD-ON EFFICACY of your novel compound is the single biggest bottleneck in preclinical drug discovery. The SDT fatty rat breaks this bottleneck by delivering a predictable, accelerated, and highly translatable human-like phenotype within a short dosing window.
Key Findings: Semaglutide Validation Data
- STRIKING RENAL PATHOLOGY IMPROVEMENT (New for ASN 2026):
A short 12-week Semaglutide treatment significantly reduced kidney hypertrophy and produced statistically significant reductions in histopathological scores for tubular atrophy, dilation, inflammation, and interstitial fibrosis.
- HEMODYNAMIC PROTECTION & GFR PRESERVATION:
Attenuated early hyperfiltration at Week 6 and prevented subsequent GFR functional decline by Week 12, accompanied by dramatic reductions in albuminuria and proteinuria.
- DUAL CARDIO-RENAL BENEFITS (HFpEF):
Significantly reduced left ventricular hypertrophy and internal dilation while restoring diastolic function (lowered E/E' ratio, increased E'/A' ratio)—proving true cardiorenal dual protection.
- COMPLETE METABOLIC CONTROL:
Sustained improvements in body weight, cumulative food/water intake, HbA1c, and fasting blood glucose.
[DOWNLOAD PRESENTATION MATERIALS]
- 📄 Official ASN Kidney Week 2026 Poster & Abstract (PDF)
(Features Novel Semaglutide Histopathology Data — Available Oct 23, 2026) - 📄 Download ADA 2026 Presentation: Semaglutide Functional & Cardiorenal Data (PDF)
(Comprehensive in vivo dataset: GFR clearance, Echocardiography & Metabolic parameters) - 📄 Download ERA 2022 Presentation: Liraglutide Baseline Cardiorenal PoC (PDF)
(Briand F. et al., "Liraglutide Improves Both Diabetic Nephropathy and Cardiomyopathy in the SDT Fatty Rat")
Struggling with Preclinical Model Limitations?
Does your current in vivo setup fail to deliver clear, decision-ready data for your R&D leadership and investors?
1. "Standard-of-Care therapies mask our compound's additive signal."
In conventional models, dosing SGLT2i or GLP-1RA alone improves disease markers so drastically that adding your novel compound yields no statistically significant difference—leaving your pipeline stalled in preclinical development.
2. "We cannot afford 50+ weeks to obtain study results."
Long dosing durations slow down your decision-making, increase housing costs exponentially, and risk losing competitive advantages in rapidly evolving CKM / DKD markets.
3. "Chemical-induction (STZ) models fail to translate to human disease."
STZ models rely on acute pancreatic beta-cell toxicity, failing to reflect the complex metabolic syndrome, obesity, and cardiorenal coupling seen in real human DKD patients.
Unrivaled Preclinical Capabilities
Figure: Clear detection of additive / combination efficacy (SoC + Candidate) on transcutaneous GFR clearance over a short dosing window.
- Spontaneous CKM Phenotype: T2D, obesity, hyperlipidemia, and progressive nephropathy without STZ artifacts.
- Short 10-12 Week Dosing Timeline: Fast turnaround for drug efficacy evaluation, dramatically reducing study costs and accelerating go/no-go decisions.
- Cardio-Renal Coupling: Simultaneous evaluation of renal lesions and left ventricular diastolic dysfunction (HFpEF).
- Fully Benchmark-Validated: Proven drug responsiveness across SGLT2i, GLP-1RAs (Liraglutide & Semaglutide), and ACEi.
- 100% Commercially Available: Supplied globally by CLEA Japan, Inc. (Est. 1965). No complex academic MTA delays or custom breeding setups.
Full Scientific Publication Archive
Access our comprehensive library of peer-reviewed papers, poster archives, and validation datasets:
Explore the SDT Fatty Rat Publication Archive:
https://www.clea-japan.com/promotion/reference_archive_en/sdt_fatty_rat_en
Turnkey Global Study Execution via CRO Partnership
Need fast, hassle-free study execution without bringing animals into your own facility?
Full study protocols—including transcutaneous FITC-sinistrin GFR clearance, echocardiography, and quantitative histopathology—can be seamlessly executed via our premier European CRO partner, Physiogenex (France), trusted by major global pharmaceutical leaders (e.g., Pfizer, Boehringer Ingelheim).
Ready to Advance Your CKM / DKD Pipeline?
📍 Visit Our Poster at ASN Kidney Week 2026 in Denver!
Meet Dr. François Briand (Physiogenex) and the CLEA Japan Scientific Team in person to discuss study designs, protocol customization, and model availability.
- Date & Time: Friday, October 23, 2026 | 10:00 AM – 12:00 PM (MDT)
- Session: Diabetic Kidney Disease: Metabolic, Mitochondrial, and Inflammatory Mechanisms [PO0601-2]
- Poster Board #: FR-PO0158 (Exhibit Hall)
* Can't make the poster session? Request a 1-on-1 private consultation with our team using the buttons below!
Discuss your study design, verify live animal inventory, or request study protocol quotes directly with our team.
